Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Enamine Extends Collaboration with UkrOrgSynthesis

Published: Thursday, April 19, 2012
Last Updated: Thursday, April 19, 2012
Bookmark and Share
Collaboration offers world's largest collection of chemical building blocks.

Enamine Ltd. and UkrOrgSynthesis Ltd have announced they have signed a collaboration agreement to offer chemical building blocks to the drug discovery industry.

By combining their catalogues, the companies become the largest global manufacturer and seller of building blocks, with 60,000 products available from stock for immediate delivery and an array of ca. 8 million tangible building blocks deliverable at fixed prices within 4-6 weeks, with synthetic success rate of 80%.

According to the terms of the agreement, UORSY products are now obtainable through Enamine, and up-to-date catalogues of in-stock and tangible building blocks from both companies are available from both Enamine and UORSY.

Enamine is now able to act as a single point of contact for requests from both catalogues, at no extra cost to customers.

Enamine and UORSY have received many requests over the years for building blocks from both in-stock and tangible collections from a wide range of pharmaceutical, agrochemical, cosmetic, and nutraceutical companies, and academic research institutions, in a continuously growing trend.

Michael Bossert, Business Development Director, said “We are confident that the collaboration extension will enable us to offer enhanced customer service, and improve the day-to-day selection, ordering and purchasing process for clients. We hope that this will result in a significant increase in market share for both Enamine and UORSY.”

He continued, “Enamine and UORSY have been working together in the design of building blocks for several years, and the extension of the collaboration for provision of logistical support from Enamine is a natural step in the business relationship.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Have Your Drug Nano-Delivered Via Microbubble
A UC engineering professor is working to develop effective nanoparticle-bubble drug delivery systems to access precise locations in the body to treat medical conditions such as cancer, eye disease and spinal disc degeneration.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos